|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 September 2000, Vol. 96, No. 6, pp. 2246-2253
NEOPLASIA
CGP57148B (STI-571) induces
differentiation and apoptosis and sensitizes Bcr-Abl-positive human
leukemia cells to apoptosis due to antileukemic drugs
Guofu Fang,
Caryn Naekyung Kim,
Charles L. Perkins,
Nimmanapalli Ramadevi,
Elliott Winton,
Sylvie Wittmann, and
Kapil N. Bhalla
From the H. Lee Moffitt Cancer Center and Research
Institute, University of South Florida, Tampa, FL; and Emory University
School of Medicine, Atlanta, GA.
The differentiation and apoptosis-sensitizing effects of the
Bcr-Abl-specific tyrosine kinase inhibitor CGP57148B, also known as
STI-571, were determined in human Bcr-Abl-positive HL-60/Bcr-Abl and
K562 cells. First, the results demonstrate that the ectopic expression
of the p185 Bcr-Abl fusion protein induced hemoglobin in the acute
myeloid leukemia (AML) HL-60 cells. Exposure to low-dose cytosine
arabinoside (Ara-C; 10 nmol/L) increased hemoglobin levels in
HL-60/Bcr-Abl and in the chronic myeloid leukemia (CML) blast crisis
K562 cells, which express the p210 Bcr-Abl protein. As compared with
HL-60/neo, HL-60/Bcr-Abl and K562 cells were resistant to apoptosis
induced by Ara-C, doxorubicin, or tumor necrosis factor- (TNF-),
which was associated with reduced processing of caspase-8 and Bid
protein and decreased cytosolic accumulation of cytochrome c (cyt c).
Exposure to CGP57148B alone increased hemoglobin levels and CD11b
expression and induced apoptosis of HL-60/Bcr-Abl and K562 cells.
CGP57148B treatment down-regulated antiapoptotic XIAP, cIAP1, and
Bcl-xL, without affecting Bcl-2, Bax, Apaf-1, Fas (CD95),
Fas ligand, Abl, and Bcr-Abl levels. CGP57148B also inhibited
constitutively active Akt kinase and NF B in Bcr-Abl-positive cells.
Attenuation of NFB activity by ectopic expression of transdominant
repressor of IB sensitized HL-60/Bcr-Abl and K562 cells to TNF-
but not to apoptosis induced by Ara-C or doxorubicin.
Importantly, cotreatment with CGP57148B significantly increased
Ara-C- or doxorubicin-induced apoptosis of HL-60/Bcr-Abl and
K562 cells. This was associated with greater cytosolic accumulation of
cyt c and PARP cleavage activity of caspase-3. These in vitro data
indicate that combinations of CGP57148B and antileukemic drugs such as
Ara-C may have improved in vivo efficacy against Bcr-Abl-positive
acute leukemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Puissant, S. Grosso, A. Jacquel, N. Belhacene, P. Colosetti, J.-P. Cassuto, and P. Auberger
Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol
FASEB J,
June 1, 2008;
22(6):
1894 - 1904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rink, A. Slupianek, T. Stoklosa, M. Nieborowska-Skorska, K. Urbanska, I. Seferynska, K. Reiss, and T. Skorski
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
Blood,
July 15, 2007;
110(2):
651 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kaufmann
Imatinib spells BAD news for Bcr/abl-positive leukemias
PNAS,
October 3, 2006;
103(40):
14651 - 14652.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Blood,
July 15, 2006;
108(2):
645 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Piwocka, S. Vejda, T. G. Cotter, G. C. O'Sullivan, and S. L. McKenna
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling
Blood,
May 15, 2006;
107(10):
4003 - 4010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Koyama, S. Koschmieder, S. Tyagi, I. Portero-Robles, J. Chromic, S. Myloch, H. Nurnberger, T. Rossmanith, W.-K. Hofmann, D. Hoelzer, et al.
Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Clin. Cancer Res.,
April 1, 2006;
12(7 Pt 1):
2025 - 2031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al.
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
Cancer Res.,
November 15, 2005;
65(22):
10536 - 10544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Appel, S. Balabanov, T. H. Brummendorf, and P. Brossart
Effects of Imatinib on Normal Hematopoiesis and Immune Activation
Stem Cells,
September 1, 2005;
23(8):
1082 - 1088.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al.
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS
J. Biol. Chem.,
July 22, 2005;
280(29):
26729 - 26734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Andreu, E. Lledo, E. Poch, C. Ivorra, M. P. Albero, J. A. Martinez-Climent, C. Montiel-Duarte, J. Rifon, J. Perez-Calvo, C. Arbona, et al.
BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells
Cancer Res.,
April 15, 2005;
65(8):
3264 - 3272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Gu, L. Santiago, and B. S. Mitchell
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl
Blood,
April 15, 2005;
105(8):
3270 - 3277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, et al.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
Blood,
February 15, 2005;
105(4):
1768 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Takagaki, S. Katsuma, Y. Kaminishi, T. Horio, T. Tanaka, T. Ohgi, and J. Yano
Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells
Genes Cells,
February 1, 2005;
10(2):
97 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guo, C. Sigua, P. Bali, P. George, W. Fiskus, A. Scuto, S. Annavarapu, A. Mouttaki, G. Sondarva, S. Wei, et al.
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
Blood,
February 1, 2005;
105(3):
1246 - 1255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Yin, Y.-L. Wu, H.-P. Sun, G.-L. Sun, Y.-Z. Du, K.-K. Wang, J. Zhang, G.-Q. Chen, S.-J. Chen, and Z. Chen
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein
Blood,
December 15, 2004;
104(13):
4219 - 4225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bali, P. George, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, A. Scuto, S. Annavarapu, W. Fiskus, et al.
Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Clin. Cancer Res.,
August 1, 2004;
10(15):
4991 - 4997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Uchida, T. Watanabe, M. Kunitama, M. Mori, S. Kikuchi, K. Yoshida, K. Kirito, T. Nagai, K. Ozawa, and N. Komatsu
Erythropoietin Overcomes Imatinib-Induced Apoptosis and Induces Erythroid Differentiation in TF-1/bcr-abl Cells
Stem Cells,
July 1, 2004;
22(4):
609 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Blood,
June 15, 2004;
103(12):
4396 - 4407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. George, P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, et al.
Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Cancer Res.,
May 15, 2004;
64(10):
3645 - 3652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al.
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clin. Cancer Res.,
January 15, 2004;
10(2):
751 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H.-J. Buhring, R. Mohle, D. Hoelzer, L. Kanz, W.-K. Hofmann, et al.
Inhibitory effect of imatinib on normal progenitor cells in vitro
Blood,
January 15, 2004;
103(2):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Beppu, J. Jaboine, M. S. Merchant, C. L. Mackall, and C. J. Thiele
Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression
J Natl Cancer Inst,
January 7, 2004;
96(1):
46 - 55.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, P. Bali, E. O'Bryan, L. Fuino, F. Guo, J. Wu, P. Houghton, and K. Bhalla
Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells
Cancer Res.,
November 15, 2003;
63(22):
7950 - 7958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kamio, T. Toki, R. Kanezaki, S. Sasaki, S. Tandai, K. Terui, D. Ikebe, K. Igarashi, and E. Ito
B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs
Blood,
November 1, 2003;
102(9):
3317 - 3322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-W. Cheong, S. Y. Chong, J. Y. Kim, J. I. Eom, H. K. Jeung, H. Y. Maeng, S. T. Lee, and Y. H. Min
Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitor, via the Activation of Mitochondria-Dependent Caspase Cascades in Human Bcr-Abl-Positive Leukemia Cells
Clin. Cancer Res.,
October 15, 2003;
9(13):
5018 - 5027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang
Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion
Clin. Cancer Res.,
October 1, 2003;
9(12):
4494 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Canitrot, R. Falinski, T. Louat, G. Laurent, C. Cazaux, J.-S. Hoffmann, D. Lautier, and T. Skorski
p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
Blood,
October 1, 2003;
102(7):
2632 - 2637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al.
Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells
Cancer Res.,
August 15, 2003;
63(16):
5126 - 5135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wong, J. McLaughlin, D. Cheng, and O. N. Witte
Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors
Blood,
May 15, 2003;
101(10):
4088 - 4097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Yu, M. Rahmani, J. Almenara, M. Subler, G. Krystal, D. Conrad, L. Varticovski, P. Dent, and S. Grant
Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells
Cancer Res.,
May 1, 2003;
63(9):
2118 - 2126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kindler, F. Breitenbuecher, A. Marx, G. Hess, H. Gschaidmeier, H. Gamm, C. J. Kirkpatrick, C. Huber, and T. Fischer
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML
Blood,
April 15, 2003;
101(8):
2960 - 2962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon, and K. Bhalla
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
Blood,
April 15, 2003;
101(8):
3236 - 3239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Salomon, S. B. Ficarro, L. M. Brill, A. Brinker, Q. T. Phung, C. Ericson, K. Sauer, A. Brock, D. M. Horn, P. G. Schultz, et al.
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry
PNAS,
January 21, 2003;
100(2):
443 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg, J. D. Griffin, and M. S. Tallman
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
82 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, E. Ng, C. Yip, W. Eisterer, Y. Chalandon, M. Stuible, A. Eaves, and C. J. Eaves
Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo
Blood,
November 15, 2002;
100(10):
3731 - 3740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nimmanapalli, E. O'Bryan, M. Huang, P. Bali, P. K. Burnette, T. Loughran, J. Tepperberg, R. Jove, and K. Bhalla
Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin
Cancer Res.,
October 15, 2002;
62(20):
5761 - 5769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Yu, G. Krystal, P. Dent, and S. Grant
Flavopiridol Potentiates STI571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells
Clin. Cancer Res.,
September 1, 2002;
8(9):
2976 - 2984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bhatia
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
Blood,
May 15, 2002;
99(10):
3792 - 3800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chalandon, X. Jiang, G. Hazlewood, S. Loutet, E. Conneally, A. Eaves, and C. Eaves
Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming
Blood,
May 1, 2002;
99(9):
3197 - 3204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, A. G. Turhan, J. Giron-Michel, | |
